(Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between the companies allowing Sanofi to buy up to 30 percent.
Regeneron shares gained 4 percent, or $11.45, to $294.01 in early trading.
The two companies have several drug development partnerships, including potential multi-billion dollar cholesterol drugs, and Sanofi had a 20.5 percent stake in Regeneron as of April 7.
Hey, check out all the research scientist jobs. Post your resume today!
